TY - JOUR

T1 - Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state

AU - Bjørn, Mads Emil

AU - Andersen, Christen Lykkegaard

AU - Jensen, Morten Krogh

AU - Hasselbalch, Hans C.

PY - 2014

Y1 - 2014

N2 - Chronic myeloproliferative neoplasms (MPN), encompassing essential thrombocythaemia (ET), polycythaemia vera (PV) and myelofibrosis (PMF), are featured by a chronic inflammatory state which is pronounced in myelofibrosis The value of YKL-40 as a biomarker of disease burden has been demonstrated in several different diseases, including cancer, diabetes mellitus and cardiovascular diseases. A state of chronic inflammation is shared by them all, YKL-40 also being involved in the severity of chronic endothelial inflammation, which today is considered of crucial importance for the development of atherosclerosis. The MPNs being cancers with a heavy burden of cardiovascular diseases we hypothesised that circulating YKL-40 might reflect the inflammatory process and potentially serve as a novel disease marker. Using ELISA, we measured YKL-40 in 15 patients with ET, 16 patients with PV, 17 patients with PMF and 30 healthy controls. YKL-40 was significantly elevated in PMF vs. control subjects, PMF levels median 43 ng/mL vs. controls median 28 ng/mL, P = 0.033. An increase from ET over PV may reflect the integrated impact of disease processes in MPNs.

AB - Chronic myeloproliferative neoplasms (MPN), encompassing essential thrombocythaemia (ET), polycythaemia vera (PV) and myelofibrosis (PMF), are featured by a chronic inflammatory state which is pronounced in myelofibrosis The value of YKL-40 as a biomarker of disease burden has been demonstrated in several different diseases, including cancer, diabetes mellitus and cardiovascular diseases. A state of chronic inflammation is shared by them all, YKL-40 also being involved in the severity of chronic endothelial inflammation, which today is considered of crucial importance for the development of atherosclerosis. The MPNs being cancers with a heavy burden of cardiovascular diseases we hypothesised that circulating YKL-40 might reflect the inflammatory process and potentially serve as a novel disease marker. Using ELISA, we measured YKL-40 in 15 patients with ET, 16 patients with PV, 17 patients with PMF and 30 healthy controls. YKL-40 was significantly elevated in PMF vs. control subjects, PMF levels median 43 ng/mL vs. controls median 28 ng/mL, P = 0.033. An increase from ET over PV may reflect the integrated impact of disease processes in MPNs.

KW - chronic inflammation

KW - YKL-40

KW - JAK2V617F

KW - myeloproliferative neoplasia (MPN)

KW - biomarker

KW - cytokines

KW - CHRONIC MYELOPROLIFERATIVE DISORDERS

KW - COLONIC EPITHELIAL-CELLS

KW - LEUKEMIA-FREE SURVIVAL

KW - JAK2 V617F MUTATION

KW - C-REACTIVE PROTEIN

KW - POLYCYTHEMIA-VERA

KW - ESSENTIAL THROMBOCYTHEMIA

KW - SERUM YKL-40

KW - ENDOTHELIAL DYSFUNCTION

KW - PLASMA YKL-40

U2 - 10.1111/ejh.12332

DO - 10.1111/ejh.12332

M3 - Journal article

VL - 93

SP - 224

EP - 228

JO - Scandinavian Journal of Haematology

JF - Scandinavian Journal of Haematology

SN - 0902-4441

IS - 3

ER -